https://scholars.lib.ntu.edu.tw/handle/123456789/621177
標題: | Cutaneous immune-related adverse events among Taiwanese cancer patients receiving immune checkpoint inhibitors link to a survival benefit | 作者: | YUNG-TSU CHO Lin, Yi-Tsz Yang, Che-Wen CHIA-YU CHU |
關鍵字: | STEVENS-JOHNSON SYNDROME; METASTATIC MELANOMA; NIVOLUMAB; MANAGEMENT; IPILIMUMAB; VITILIGO; THERAPY | 公開日期: | 2022 | 出版社: | NATURE PORTFOLIO | 卷: | 12 | 期: | 1 | 來源出版物: | Scientific reports | 摘要: | Cutaneous immune-related adverse events are common in cancer patients receiving immunotherapies but seldom studied in a comprehensive way of collecting all cancer types with comparisons between different immune-oncology drugs and correlation to patient survival. In this retrospective cohort study, we recruited 468 cancer patients receiving immunotherapies in a tertiary referral center in Taiwan and try to determine real-world incidence of cutaneous immune-related adverse events and their associations with the survival rates. Among them, 128 patients (27.4%) had cutaneous immune-related adverse events, with maculopapular eruption (10.6%) and pruritus (10.1%) most frequently identified in the monotherapy group. The incidence of these cutaneous immune-related adverse events was highest in patients receiving pembrolizumab (34.1%, P < .0001). Concurrent usage of molecular-targeted therapy with immunotherapy was associated with a higher incidence (57.8%, P < .0001). The Kaplan-Meier plot and log-rank test showed that patients with any type of immune-related cutaneous adverse events had longer survival time than those without (P < .0001). In conclusion, having either type of cutaneous immune-related adverse event in cancer patients receiving immunotherapies was correlated with a longer overall survival. Prompt diagnosis and suitable treatment are important. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/621177 | ISSN: | 2045-2322 | DOI: | 10.1038/s41598-022-11128-5 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。